Abstract: Natural products are often used in drug development due to their ability to form unique and diverse chemical structures. Coumestans are polycyclic aromatic plant secondary metabolites containing a coumestan moiety, which consists of a benzoxole fused to a chromen-2-one to form 1-Benzoxolo[3,2-c]chromen-6-one. These natural compounds are known for large number of biological activities. Many of their biological effects can be attributed to their action as phytoestrogens and polyphenols. In the last decade, anticancer effects of these compounds have been described in vitro but there is only limited number of studies based on models in vivo. More information concerning their in vivo bioavailability, stability, metabolism, toxicity, estrogenicity, cellular targets and drug interactions is therefore needed to proceed further to clinical studies. This review focuses on coumestans exhibiting anticancer properties and summarizes mechanisms of their toxicity to cancer cells. Moreover, the possible role of coumestans in cancer prevention is discussed.
also acts as antioxidant [18, 36] and prevents bone resorption by inhibiting differentiation and function of osteoclasts and by supporting proliferation, differentiation and function of osteoblasts [37] [38] [39] [40] [41] [42] . In addition, it inhibits adipocyte differentiation and lipogenesis [43, 44] , affects insulin sensitivity, lipid and glucose metabolism [45] [46] [47] [48] , antagonizes pregnane X receptor (PXR) [49, 50] , inhibits aryl hydrocarbon receptor (AhR) activation by environmental contaminants [51] , and regulates steroid metabolism by inhibiting aromatase and 17β-hydroxysteroid dehydrogenase [52] [53] [54] . Coumestrol was also shown to be involved in epigenetic control of gene expression by deregulating methylation of specific genes in female rat pancreas [55] .
Many of the coumestrol effects mentioned above are mediated by estrogen receptors (ERs). Numerous studies demonstrated that coumestrol is a phytoestrogen acting as agonist of both ERα and ERβ with stronger binding affinity to ERβ [19, 56, 57] . The coumestrol binding affinity to ERα is weaker in comparison to endogenous 17β-estradiol (E2) [19, 58] . On the other hand, binding affinity of these two compounds to ERβ is similar [19, 59] . The effects of ERα and ERβ on tumor growth, metastases and chemosensitivity are different reflecting regulation of various genes by binding to distinct regulatory elements recruiting distinct coregulators and chromatin remodelling factors. Several findings, reviewed by Leitman et al. and Burns et al. , demonstrated that expression/ activation of ERβ can modulate or even oppose pro-proliferative effects of ERα [60, 61] . The anti-proliferative and anti-metastatic effects of phytoestrogens may be therefore explained by their higher affinity to ERβ compared to ERα [61] [62] [63] .
Both genomic and nongenomic mechanisms have been proposed to mediate phytoestrogenic effects of coumestrol (Fig. 3) . Coumestrol binds to nuclear ERs and induces expression of specific estrogen-responsive genes that regulates various cellular processes, such as growth and survival [63, 64] . A strong correlation between expression profiles induced by coumestrol and E2 in ERα-expressing cancer cells was reported but was less obvious in the presence of ERβ, suggesting that activation of ERβ by coumestrol can modulate its ERα-stimulating effects in cells [63] . Coumestrol can also initiate signaling from the membrane ERs by activation of ERK1/2, JNK, PI3K, Syc and changes in Ca 2+ fluxes [65] [66] [67] [68] [69] [70] .
Phytoestrogens often exert biphasic effect on the ER-responsive cancer cells [71] . Coumestrol in doses lower than 10 -7 M enhances proliferation of breast and pituitary cancer cells by stimulation of the G1/S cell cycle transition, cyclin D1 over-expression along with ERK 1/2 and JNK phosphorylation. These effects are inhibited by the ER antagonist ICI 182,780 [69, [72] [73] [74] . At higher doses, however, coumestrol induces apoptosis/cell death of breast, pancreatic, ovarian, and prostate cancer cells. The induction of apoptosis by coumestrol is associated with caspase activation and downregulation of antiapoptotic Bcl-2 protein [35, 65, 66, 72, 75, 76, [77] [78] [79] .
As phytoestrogens directly interacts with ERs, it has been suggested that they can block binding of endogenous estrogen and thus act as estrogen antagonists. This antagonism in binding to ERs was suggested for coumestrol as well [56, 57, 80] . However, coumestrol did not inhibit the E2-mediated gene transactivation from ERE (estrogen responsive element) and the E2-induced proliferation of breast cancer and HeLa cells [71, 80, 81] . Moreover, in some of these studies, additive effects of both compounds were reported [82, 83] . Interestingly, coumestrol at very low doses attenuated the proliferative effects of E2 in rat pituitary cells [69] . These contradictory results may reflect differences in doses of coumestrol and estrogens, cell and tissue specificity, the type of reporter assays, the presence/absence/activity of ERcoactivators, the ratio of ERα/ERβ or may also reflect multiple mechanisms of action of coumestrol in cells. Numerous studies reported that coumestrol acts as phytoestrogen and endocrine disrupter in vivo by affecting several endocrine mechanisms during the estrous cycle resulting in abnormalities in the development of male and female reproductive tracts and infertility. Pathologies, such as lack of ovulations, cervical and uterine lesions and paraovarian cysts have been referred in lambs, ewes, rats, mice and mares fed with a diet rich in coumestrol [84, 85] . Although coumestrol acts as ER agonists, it does not affect activity of androgen-, progesterone-, glucocorticoid-and thyroid receptors. However, it does affect their expression [79, [86] [87] [88] .
Although it has been previously suggested that coumestrol exerts its antiproliferative effect by competitive binding to ER [89] , cytotoxicity of coumestrol was also observed in ER-negative cell lines [76, 90, 91] . There are several molecular targets related to the coumestrol-induced cell cycle block and apoptosis. Coumestrol inhibits activity of cassein kinase II (CKII) both in vitro and in various cancer cells [91, 92] . CKII is Ser/Thr kinase that catalyzes phosphorylation of more than 300 cytoplasmatic and nuclear proteins. CKII regulates multiple cellular processes including cell proliferation, survival and RNA synthesis [93] [94] [95] [96] . Expression of CKII is upregulated in variety of tumor cells, thus representing a favorable target for cancer therapy [97] . Indeed, inhibition of CKII activity resulted in direct induction of apoptosis or increased sensitivity to various chemotherapeutics [98] [99] [100] . Liu et al. demonstrated that coumestrol inhibits growth and induces apoptosis of three cancer cell lines (A549, Jurkat and HeLa) at least partially through down-regulation of the CKII-specific Akt phosphorylation. Furthermore, coumestrol-induced senescence of breast cancer MCF-7 and colon cancer HCT116 cells was antagonized by overexpression of CKII [91] . Inhibition of CKII by coumestrol resulted in activation of NADPH oxidase, reactive oxygen species (ROS) production and activation of the p53-p21 (Cip1/WAF1) pathway resulting in cellular senescence [92] .
Coumestrol interacts with DNA [101] and posses mutagenic and clastogenic properties. It induces mutations in TA97 and TA102 strains of Salmonella typhimurium [102] as well as DNA strand breaks, chromosomal aberrations, micronuclei and somatic mutations in Chinese hamster V79 cells, Syrian hamster embryo cells, human lymphocytes and human lymphoblastoid cells [103] [104] [105] [106] . Although inhibition of topoisomerase II as mechanism of the coumestrol-induced clastogenicity was suggested [103, 105] , this hypothesis has not been proved yet.
Coumestrol also inhibits invasion of MDA-MB 231 breast carcinoma cells but mechanism of this effect is not known [90] . Coumestrol is an inhibitor of α-glucosidase [107] . The α-glucosidase inhibitors disrupt biosynthesis and structure of oligosacharides on cell surface. The cell surface oligosacharides are important regulators of various steps of the cancer metastasis process and the glucosidase inhibitors suppress the metastatic spreading of malignant tumor cells by perturbing correct carbohydrate arrangement [108] . In addition, coumestrol potentiates association of E-cadherin with β-catenin, restores integrity of adherent junctions and prevents the Apc-associated intestinal tumorigenesis in the mouse colorectal cancer Apc(Min/+) model. Coumestrol also significantly improves rate of the enterocyte crypt-villus migration [109] . In pancreatic tumor cells, coumestrol was shown to decrease expression of K-ras, an oncogene promoting cell invasivity [66] . As mentioned above, coumestrol is an antagonist of PXR that can block the effects of PXR agonists [49] . PXR is a nuclear receptor protein monitoring the presence of foreign toxic substances and upregulating expression of proteins involved in their intracellular transport and metabolic detoxification. Interestingly, PXR regulates expression of the cytochrome P450 3A gene coding for a key enzyme of phase I drug metabolism that is involved oxidative metabolism of significant portion of drugs and xenobiotics [110] . Coumestrol also inhibits expression and/or function of xenobiotic transporters including breast cancer resistance protein (BCRP) and multidrug resistance gene (mdr-1) [66, 111] . Therefore, it can be anticipated that coumestrol may affect the effectiveness of chemotherapy of cancer.
With respect to the ER-targeted therapy of breast cancer, coumestrol differently affects growth of tamoxifen-resistant and tamoxifen-sensitive breast cancer cells. Moreover, it also abrogates the growth-inhibitory effect of tamoxifen in tamoxifen-sensitive cells [112] . Interestingly, the interaction between tamoxifen and coumestrol in regulation of ER transcription activities depends on mutational status of ER [81] .
WEDELOLACTONE AND DEMETHYLWEDELOLACTONE
Wedelolactone (Fig. 2) [113] [114] [115] [116] [117] . Recently, extracts of Wedelia chinensis and a mixture of its compounds (wedelolactone, apigenin, luteolin) exhibited growth-inhibitory effect on prostate cancer cells in vitro and in vivo [118] . Very recently, wedelolactone and its derivative demethylwedelolactone have been shown to inhibit invasive growth and metastasis of breast cancer xenografts [119] . Demethylwedelolactone (Fig. 2) , which has not been characterized so far, appears to be even more potent antitumor agent compared to wedelolactone itself [119] . In vitro, wedelolactone inhibited growth and induced cell death of breast, pituitary, colon, liver, neuroblastoma, myeloma and prostate cancer cell lines [120] [121] [122] [123] [124] [125] .
Numerous cellular molecules and signaling pathways were suggested to be targeted by wedelolactone. Wedelolactone acts as an inhibitor of IKK kinase, the key enzyme regulating the activity of NFκB [5]. This transcription factor, a key regulator of cancer cell survival, growth, invasion, metastasis and angiogenesis, is often constitutively active in cancers [126, 127] . Suppression of the NFκB activity by natural compounds, such as curcumin, resveratrol, capsaicin and wedelolactone is believed to inhibit the oncogenic potential of transformed cells [119, 123, 127] . Genes coding for matrix metalloproteinases (MMPs) were identified among the NFκB-regulated and the wedelolactone-inhibited genes thus linking the wedelolactone-treatment to inhibition of breast cancer cell invasion and metastasis [119] .
Androgen receptor is another target of wedelolactone identified in prostate cancer cells. Wedelolactone inhibited its activities and exerted stronger growth-suppressing effect in androgen-dependent prostate cancer cell lines when compared to androgen-independent cells. Moreover, a synergistic inhibitory effect with apigenin and luteolin was observed [128] .
Wedelolactone also inhibits activity of 5-lipoxygenase (5-Lox), an enzyme that catalyzes the first step in biosynthesis of leukotrienes from arachidonic acid [129] . Previous studies have demonstrated an essential role of 5-Lox in regulation of proliferation and survival of various types of cancer cells [130] . Sarveswaran et al. reported that the wedelolactone-induced caspase-dependent apoptosis of prostate cancer cells was effectively prevented by 5-oxoETE, a metabolic product of 5-Lox [124] . In this study, authors also reported that wedelolactone inhibited PKCε, activated JNK and had no effect on the Akt kinase activity. The functional role of JNK was subsequently confirmed, since specific JNK inhibitor suppressed the wedelolactone-induced apoptosis [124] .
There are multiple effects of wedelolactone on cell signaling pathways. It significantly increases phosphorylation of ERK and JNK in hepatic stellate cell line LX-2 [117] , ERK but not JNK in mesenchymal stem cells [131] and decreases phosphorylation of ERK in breast cancer MDA-MB-231 cells [119] . Wedelolactone enhances the antitumor activity of IFN-γ in colon a hepatocarcinoma cell lines through inhibition of STAT1 dephosphorylation by T-cell protein tyrosine phosphatase [125] . The inhibition of breast cancer cell motility by wedelolactone was attributed to its inhibitory effect on phosphorylation of focal adhesion kinase (FAK) [119] .
We have recently shown that wedelolactone acts as a catalytic inhibitor of DNA topoisomerase IIα, the essential enzyme for cell proliferation, by blocking its binding to supercoiled plasmid DNA [132, 133] . Furthermore, we showed that the topoisomerase IIα-inhibitory effect of wedelolactone is redox-dependent as it is suppressed by reducing agents. Reducing agents, such as Nacetylcysteine (NAC) and glutathione also lower cytotoxicity of wedelolactone to breast cancer cells. We have also documented DNA damage induced by wedelolactone in vitro upon its oxidation by copper ions [133] .
Wedelolactone senzitizes pancreatic cancer cells to proapoptotic effects of TNFα by inhibiting the NFκB activity and decreasing expression of Mcl-1, a member of the Bcl-2 protein family [134] . Other members of the Bcl-2 protein family including Bax and Bcl-2 were deregulated by wedelolactone in hepatic stellate cell line LX-2 [117] .
Although wedelolactone is widely considered to act as phytoestrogen [30, 135] , to our knowledge there has not been published any direct evidence for this statement. Interestingly, no transactivation of the luciferase reporter gene from ERE occurred in breast cancer MCF-7 cells treated with wedelolactone in media containing 10% FCS [131] . However, as previous studies showed that the weak stimulatory effect of phytoestrogens on cell growth and ERE transactivation in ER-responsive cells such as MCF-7 could be detected only in steroid-deprived conditions, the experiments by Lim et al. may not detect proestrogenic effects of wedelolactone.
PSORALIDIN
Psoralidin (Fig. 2) is a coumestan isolated from seeds of Psoralea corylifolia (Leguminosae) [22] . This plant is used in traditional medicine for treatment of pollakiuria, nephritis, osteoporosis, hypertension, asthma, leucoderma, leprosy and psoriasis. Extracts from the seeds and roots of Psoralea corylifolia exhibits antimicrobial, antifungal, antihelmintic, antioxidative, immunomodulatory, laxative, antidepressant, estrogenic and anticancer properties [6] [7] [8] [9] [10] [11] . Although these extracts contain numerous bioactive compounds including various flavonoids, terpenes and coumarins [11] , psoralidin is one of compound with described anticancer properties.
Psoralidin is cytotoxic agent inducing apoptosis of prostate [136, 137] , gastric [22] , colon, and breast [138] cancer cells. Oral administration of psoralidin significantly reduces growth of prostate cancer tumor xenografts in nude mice [136, 139] .
Psoralidin induces production of ROS in prostate cancer cells but not in normal prostate epithelial cancer cell line without altering expression and activity of endogenous antioxidant defense enzymes, such as catalase and superoxide dismutase 1 and 2 (SOD1 and SOD2) [140] . Psoralidin induces apoptosis of prostate cancer cell lines characterized by decreased mitochondrial membrane potential, released cytochrome c into cytosol, activation of caspases 3, 8 and 9, increased expression of Bax and decreased expression of Bcl-2 [136, 140] . Ectopic overexpression of antioxidant defense enzymes or treatment with NAC reduces the psoralidin-induced ROS production and the psoralidin-induced death of prostate cancer cells. By similar approaches authors demonstrated that psoralidin inhibits cell migration, invasion and expression of epithelialmesenchymal transition (EMT) markers slug, vimentin and β-catenin in these cells [140] .
There are increased ROS levels in cancer cells compared to normal cells resulting from their accelerated metabolism. The high ROS levels can have protumorigenic effects but at the same time they also render cancer cells more susceptible to the oxidative stress-induced cell death. Exogenous compounds that increase oxidative stress by disturbing balance between ROS production and scavenging may therefore cause cell damage in cancer cells more efficiently [141] . Interestingly, about half of the cancer chemotherapy drugs approved by the FDA until 2007 have been reported to cause oxidative stress [142] .
Psoralidin senzitizes cancer cells to apoptosis induced by the tumor necrosis factor α (TNF-α) ligand superfamily. Slizska et al. and Bronikowska et al. reported enhancement of the TRAILinduced apoptosis in prostate and cervical cancer cells [137, 143] . Srinivasan et al. described similar effect of psoralidin in the TNFinduced apoptosis of prostate cancer cells [136] . The mechanism of cell senzitization to the TNF ligand superfamily by psoralidin possibly include deregulation of death receptors, FADD, Bid, Bax, Fas, FasL, XIAP, cIAP1/2 and Bcl-2 expression and inhibition of NFκB activation/expression [136, 137] .
Psoralidin also inhibits the LPS-induced overexpression of inducible nitric oxide synthase (iNOS) and production of nitric oxide by macrophages by interfering with activation of the PI3K/Akt/NFκB signaling pathway [144, 145] . Inhibitory effect of wedelolactone and coumestrol on iNOS production in stimulated immune cells was also observed [17, 146] . Whether the effect of coumestans on nitric oxide production may have any relevance for cancer progression/treatment is unclear. NOS are produced in various types of cancers and nitric oxide can enhance cancer progression by its promutagenic, antiapoptotic, proinvasive and proangiogenic effects. Nevertheless, cytostatic and cytotoxic action on cancer cells has been also reported. This dual role of nitric oxide in cancer progression has been recently summarized by Choudhari et al. [147] . Psoralidin was also described to inhibit the prosurvival PI3K/Akt/NFκB signaling pathway in prostate cancer cells [148] , however, this article was subsequently retracted. The PI3K/Akt/ NFκB signaling is a key regulator of cell cycle progression, cell survival, chemosensitivity, radiosensitivity and metastasis. Numerous drugs of low molecular weight that inhibit pathway are being developed and tested in preclinical and clinical studies [149, 150] .
Besides its effect on the PI3K/Akt/NFκB pathway, psoralidin also inhibits the EGFR/MAPK/ERK signaling and activates SAPK/JNK in prostate cancer cells and mouse tumor xenografts. The functional significance of SAPK/JNK in psoralidin-induced apoptosis was confirmed by using the JNK-specific inhibitor SP600125 and c-Jun-specific siRNA [139] .
Psoralidin also inhibits protein tyrosine phosphatase 1B [151] . As the role of this protein in carcinogenesis is still matter of debate [152] , it is not clear whether this function of psoralidin could contribute to its anticancer effects.
GLYCYROL
Only few studies describing possible anticancer and cytotoxic affects of glycyrol have been published so far. Glycyrol (Fig. 2) is a coumestan isolated from Glycyrrhiza uralensis with antibacterial, antiinflammatory and immunosuppressive activities [12] [13] [14] . The latter two were attributed to ability to inhibit activities of calcineurin, NFκB and deregulation of expression of iNOS, COX-2, IL-1, IL-2, IL-6 and TNF-α [13, 14] . Glycyrol induced apoptosis of human embryonic kidney 293T and Jurkat leukemia cells by inhibition of the NFκB activity, S-phase arrest, activation of caspases and enhancement of Fas but not Bcl-2 or Bax proteins [153, 154] .
COUMESTANS IN CANCER PREVENTION
Majority of studies analyzing chemopreventive effects of coumestans were focused on coumestrol. Since it is present in legumes and soya, ingestion of these nutrients increase its concentrations in serum and urine. The reported average serum concentration of coumestrol in human populations from Asia is approximately 10 -8 M [155] . As stated above, coumestrol acts as phytoestrogen within this concentration range. The effect of phytoestrogens intake on cancer risk is still matter of intense debate and was recently reviewed excellently [156, 157] . Despite the numerous studies published in the last decade, there is no clear consensus regarding the cancer preventive effects of phytoestrogens although some meta-analyses reported protective effects with safe side-effects profiles [158] [159] [160] [161] . We still lack an evidence that cancer incidence is affected by intake of phytoestrogens or whether associations observed in previous studies just point to the role of phytoestrogens as markers of healthy diet [156, 157] .
Besides its role as a phytoestrogen, coumestrol as well as other coumestans may be chemopreventive also by acting as polyphenols. Polyphenols affect numerous cellular targets and signaling pathways that are related to tumorigenesis including cell proliferation, cell death, inflammation, dissemination, angiogenesis, or chemo-and radioresistance [162] . These compounds can act both as antioxidants or prooxidants. Many mechanisms have been proposed for prevention of oxidative stress and ROS generation by polyphenols but radical scavenging and metal chelation are the most widely published mechanisms for their antioxidant activity. The prooxidant activity is largely attributed to the ability of polyphenolic compounds to bind and reduce Fe 3+ or Cu 2+ with subsequent production of semiquinone/quinone radicals and ROS [163, 164] . Based on observation of increased concentration of cellular copper in tumors, the production of ROS by copper-initiated redox cycling of polyphenols was suggested to be enhanced in cancer cells. This may result in preferential toxicity of polyphenolic compounds to cancer cells resulting in their chemotherapeutic as well as chemopreventive properties [163] .
The radical scavenging activity of coumestans is relatively high compared to many other phytocompounds [9, 36] . Coumestrol prevents cell damage, reduces ROS production, lipid peroxidation, mutagenicity but increases glutathione level, SOD activities and survival of cells challenged with oxidative stress [165] [166] [167] . Moreover, coumestans can induce expression of quinone reductase, a phase II detoxifying enzyme blocking generation of mutagenic quinone metabolites and carcinogens [168, 169] .
Nevertheless, many reported effects claimed for polyphenols are controversial, since correlations between their effects in vitro and in vivo are poorly established. Orally administered polyphenols undergo rapid and extensive conjugation in the intestinal tract. Once absorbed, polyphenols are further metabolized by the liver and modified by methylation, glucuronidation, and sulfation. Although some exceptions have been reported, most published data indicate that natural polyphenols are biologically more active than their metabolites. Poor bioavailability, excessive modification and limited distribution in the organism therefore complicate the use of polyphenols in clinical studies. Pharmaceutical formulations of polyphenols aiming to improve their absorption, pharmacokinetics, efficacy and delivery are under testing [162] . In conclusion, although there are plenty of pre-clinical and clinical studies reporting the positive role of polyphenols in cancer prevention and treatment, more long-term, randomized and controlled dietary intervention studies are necessary to fully evaluate the benefit of polyphenol intake [170] .
Contradictory data about coumestrol and cancer risk were published (data summarized in Table 1 ). No association between coumestrol intake and breast [171] [172] [173] , ovarian [174] , testicular [175] , thyroid [176] and endometrial [177, 178] cancer in retrospective case-control studies has been reported. On the other hand, other authors reported an inverse association between coumestrol intake and the risk of prostate, gastric and glioma cancers [179] [180] [181] . Hedelin et al. described an inverse association between coumestrol intake and prostate cancer but only for carriers of C allele of the -13950 ERβ promoter polymorphism in the retrospective case-control study [182] . In prospective studies, no association between coumestrol intake and breast cancer was reported by Touillaud et al. [183] . Similarly, no association between coumestrol intake and ovarian cancer was reported in prospective, population-based study in Sweden. However, in this study a marginally significant difference in the coumestrol intake between patients with invasive and low-malignant ovarian cancer was reported [184] . Another large retrospective study of the same group found no association between coumestrol intake and the risk of overall breast cancer. Interestingly, an inverse association between coumestrol intake and the incidence of ER-, PR-negative breast tumors was reported in this study [185] . Inconsistency of these studies may reflect differences in the study design, sample size, ethnic homogeneity, hormonal status, length of folow-up, etc. Direct comparison between nutrition studies is also limited by differences in databases of natural compounds as these often differ in calculation and analytical methods, references, phytoestrogen content in food items, etc. [185] .
Furthermore, it seems that studying only one isolated phytochemical may be inappropriate because to reduce cancer risk the phytochemicals may act synergistically with other dietary components, such as other plant compounds, vitamins, minerals, etc. This synergism between nutrition compounds complicates identification of specific factor(s) that contributes to observed associations [156] . Moreover, various phytochemicals share common mechanisms in regulation of cellular processes. Therefore, combination of natural compounds may solve the problems with bioavailability, distribution and toxicity of individual compounds. Lowering the dose of each compound and multitarget therapy are additional benefits of combined treatment. Understanding the synergistic mechanisms of phytocompounds may be of great significance for their use in modern medicine opening broad perspectives for "networking pharmacology" [186] . Synergic effects between coumestans and other phytochemicals with respect to cancer treatment were documented [118, 187] .
SUMMARY
Coumestans are large family of phytocompounds with numerous biological effects. While initial studies were mostly interested in coumestrol due to its high content in food and the observed effects on reproduction of livestock, studies performed in the last decade have characterized biological properties of other members of the coumestan family. These studies clearly demonstrated anticancer properties of these compounds in vitro (summarized in Table 2 ) but only limited number of studies on in vivo models was published. Chemopreventive and anticancer therapy enhancing effects of coumestans were also described. Many of their biological effects can be attributed to their action as phytoestrogens and polyphenols. However, majority of anti-cancer effects of coumestans were demonstrated in vitro using pure natural compounds and only limited data are available about absorption, metabolism and bioavailability of coumestans in human body. Therefore, data showing anticancer effects of coumestans should be interpreted with caution. More information about their in vivo bioavailability, stability, metabolism, toxicity, estrogenicity, cellular targets and drug interactions is needed to proceed further to clinical studies. 
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